O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). (2nd July 2019)

Record Type:: Journal Article
Title:: O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). (2nd July 2019)
Main Title:: O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Authors:: Miksad, R
Cicin, I
Chen, Y
Klumpen, H
Kim, S
Lin, Z
Youkstetter, J
Sen, S
Cheng, A
Meyer, T
Kelley, R
Abou-Alfa, G
Abstract:
Is Part Of:: Annals of oncology. Volume 30(2019)Supplement 4
Journal:: Annals of oncology
Issue:: Volume 30(2019)Supplement 4
Issue Display:: Volume 30, Issue 4 (2019)
Year:: 2019
Volume:: 30
Issue:: 4
Issue Sort Value:: 2019-0030-0004-0000
Page Start:
Page End:
Publication Date:: 2019-07-02
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdz154.021 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12154.xml